UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
UroGen Pharma (Nasdaq: URGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference, held June 8–10, 2026.
Rhea-AI Summary
UroGen Pharma (Nasdaq: URGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference, held June 8–10, 2026.
Management is scheduled for a fireside chat and 1x1 investor meetings on June 10, 2026 at 8:40 AM ET in Miami Beach, FL, with a webcast and 90-day replay.
Positive
- None.
Negative
- None.
Details
News Market Reaction – URGN
In the Jun 2 session, URGN declined 1.81%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference dates
- June 8–10, 2026
- Goldman Sachs 47th Annual Global Healthcare Conference
- Company session time
- 8:40 AM ET
- URGN fireside chat on June 10, 2026
- Conference edition
- 47th
- Goldman Sachs Annual Global Healthcare Conference
- Webcast replay length
- 90 days
- Replay availability on UroGen corporate website
Historical Context
-
UGN-103 showed 94.5% six‑month DOR in recurrent LG-IR-NMIBC Phase 3 trial.
-
ZUSDURI ENVISION data showed 64.5% 36‑month DOR with median not yet reached.
-
Announced participation in three May 2026 investor conferences with webcast access.
-
Q1 2026 revenue reached $51.0M with strong ZUSDURI and JELMYTO contributions.
-
Announced May 6, 2026 earnings release and conference call logistics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.
Goldman Sachs 47th Annual Global Healthcare Conference
| Date / Time: | June 10, 2026, at 8:40 AM ET |
| Format: | Fireside chat and 1x1 investor meetings |
| Location: | Miami Beach, FL |
| Webcast Link: | here |
The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is approved for adult patients with recurrent LG-IR-NMIBC. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.